readthroughSign in
Nov 16, 2026Quarterly update

Moleculin completes enrollment in Part A of pivotal MIRACLE AML trial, eyes Q1 2027 data

The company finished treating all 90 patients in the first stage of its Phase 2/3 Annamycin trial and still expects comprehensive results in the first quarter of 2027.

Moleculin Biotech reported on November 16, 2026 that it had completed treatment for all 90 patients in Part A of its pivotal MIRACLE trial evaluating Annamycin.1 The company said it remains on track to report comprehensive Part A data in the first quarter of 2027, data expected to support selection of the optimal Annamycin dose for advancement into Part B, currently planned to begin in the first half of 2027.1

The trial, known as MIRACLE (MB-108), is a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia.1

Moleculin also pointed to a peer-reviewed cardiac safety analysis. It said it had published a peer-reviewed analysis in Frontiers in Cardiovascular Medicine evaluating cardiac safety findings from 90 patients treated with Annamycin across five clinical trials in AML and metastatic soft tissue sarcoma, which, as independently evaluated by a cardio-oncology laboratory at Cleveland Clinic, found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.1

Separately, the company presented new preclinical findings at an AACR pancreatic cancer conference, reporting that Annamycin's antitumor activity in pancreatic cancer models is partially mediated by CD8+ T cell cytotoxicity, suggesting the drug may help expose immunologically "cold" tumors to immune attack, potentially supporting combination treatment approaches.1 Moleculin also said data from MIRACLE had been accepted for presentation at the 2026 American Society of Hematology Annual Meeting, highlighting interim results from the pivotal trial.1

On financials, the company reported cash and cash equivalents of approximately $7.3 million as of September 30, 2026, compared to approximately $8.9 million as of December 31, 2025,1 with net cash used in operating activities for the nine months ended September 30, 2026 of approximately $21.7 million.1 Moleculin disclosed in its forward-looking statements that it will require significant additional financing, for which it has no commitments, to conduct its clinical trials as described in the release.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.